Figure 6.

A. Adipose differentiation of HEY PGCCs in vitro and in vivo. Staining of regular HEY cell and PGCCs with oil red O (a and b) or FABP4 (c and d) following incubation with adipogenesis medium. (e) Histopathology of PGCC-derived xenograft tumors (H&E, 20×) and immunohistochemical staining against FABP4 (f). (g and h) immunohistochemical staining against human-specific vimentin (g:10× and h:20×). B. Cartilage differentiation of HEY PGCCs in vitro. (a) Regular HEY cells cultured in chondrogenesis medium (10×). (b) Formation of chondrogenic pellets from PGCCs cultured in chondrogenesis medium (10×). Chondrogenic pellets stained with (c) Alcian blue and (d) Alcian blue/PAS (10×). C. Cartilage and bone differentiation in vivo. (a) Cartilage-like tumor near the rib cage in nude mice. (b)Bony differentiation on sections stained with H&E (10×), (c) Safranin red and fast green (10×), and (d) anti-eGFP (10×). (e) Formation of loose tumor bodies in the abdomen following injection of chondrogenic pellets. (f) Histopathology of the loose tumor bodies (10×). (g) Cartilage differentiation (black arrow heads, 10×). (h) Bony differentiation revealed by anti-osteopontin staining (10×). D. Osteogenesis, chondrogenesis and adipose differentiation of MDA-MB-231 PGCCs. (a) Chondrogenic pellets of MDA-MB-231 PGCCs cultured with chondrogenesis medium (10×). Chondrogenic pellets stained with (b) Alcian blue and (c) Alcian blue/PAS (10×). (d) Formation of loose tumor bodies following abdominal injection of pellets. (e) Computed tomography image showing osteogenesis differentiation (white arrow heads). (f) Calcification of tumor derived from MDA-MB-231 PGCCs (black arrow heads) (10×). (g) Osteoid differentiation revealed by anti-osteopontin staining in loose bodies (10×). (h) Adipose differentiation revealed by human specific anti-vimentin staining in loose bodies (20×).